A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis).

Similar documents
THROMBOTIC MICROANGIOPATHY. Jun-Ki Park 7/19/11

DRUG NAME: Eculizumab Brand(s): Soliris DOSAGE FORM/ STRENGTH: 10 mg/ml (300 mg per vial)

What is meant by Thrombotic Microangiopathy (TMA)?

Year 2004 Paper one: Questions supplied by Megan

Thrombotic Microangiopathies (TMA) / TTP/HUS/αHUS Pathology & Molecular. Genetics

Hemolytic uremic syndrome: Investigations and management

Some renal vascular disorders

Fußzeile (Titel der Präsentation) 1. Thrombotic Microangiopathy: The German Experience 4. Conflictof interest: none

A 36 year old previously healthy female develops fever and ruising

Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura

A 60 year old woman with altered mental status and thrombotic microangiopathy. Josh Veatch

Approccio morfologico alle microangiopatie trombotiche

R. Coward has documented that he has received cooperative grants from Takeda and Novo Nordisk

New insights in thrombotic microangiopathies : TTP and ahus

Thrombotic microangiopathies and antineoplastic agents

Corporate Medical Policy

Atypical Hemolytic Uremic Syndrome: When the Environment and Mutations Affect Organ Systems. A Case Report with Review of Literature

Renal failure and thrombocytopaenia? Don t forget TTP/HUS. Jonathan Wala Nephrologist

Soliris (eculizumab) DRUG.00050

Clinical Study Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

DR V PHILIP CLINICAL HAEMATOLOGY UNIT CHRIS HANI BARAGWANATH ACADEMIC HOSPITAL

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

Let`s go for the diagnosis! Yazeed Toukan, MD Pediatric Pulmonary Institute, Ruth Rappaport Children`s Hospital July 2016

HEME 10 Bleeding Disorders

* Renal insufficiencies

Case Studies. Scleroderma Renal Crisis or Thrombotic Thrombocytopenic Purpura: Seeing Through the Masquerade. Patient 1

Primary causes: Complement dysregulation (50% of non-shiga toxin-producing E. coli ) Secondary causes:

Presentation Outline. Disease Background Previous research on platelet recovery rate Goal of our study Methods Results Limitations Conclusions

Case report 24 th Summer School of Internal Medicine 2015

Dr. E.SUDHA (Fellow in Pediatric Nephrology) DEPT OF PEDIATRIC NEPHROLOGY & DIALYSIS Dr.MEHTA CHILDRENS HOSPITAL

ahus A PATIENT S GUIDE To learn more about ahus, visit Copyright 2011, Alexion Pharmaceuticals, Inc. All rights reserved.

Thrombotic Microangiopathies

Dr Ian Roberts Oxford

Hemolytic uremic syndrome

Non-immune acquired haemolytic anaemias. Dr.Maysem

Microangiopatia trombotica (MAT) e Sindrome emolitico-uremica atipica (SEUa): Basi patogenetiche, inquadramento diagnostico e principi del

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST

Thrombotic Thrombocytopenic Purpura and the Role of ADAMTS-13

Accepted Manuscript. No more thrombotic thrombocytopenic purpura/hemolytic uremic syndrome please. Yeong-Hau H. Lien MD, PhD S (18)

Thrombotic Thrombocytopenic

Things to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC

TMA in HUS and TTP: new insights

Cigna Drug and Biologic Coverage Policy

Putting the Pieces Together. Anne Longtine MD Internal Medicine Residency, Maine Medical Center Maine ACP Annual Meeting Clinical Vignette 9/16/2017

Chronic Active Thrombotic Microangiopathy in Native and Transplanted Kidneys

SHIGA-TOXIN PRODUCING ESCHERICHIA COLI STEC Update. Roshan Reporter, MD, MPH Rita Bagby, PS-PHN Leticia Martinez, PS-PHN

HUS and TTP Testing. Kenneth D. Friedman, M.D. Director, Hemostasis Reference Lab BloodCenter of Wisconsin, Milwaukee WI

LAMA SHATAT TTP, ITP, DIC

Symposium. Acute Kidney Injury with Thrombocytopenia. Lalitha A V*, Suryanarayana G**, Sumithra S***

A Rational Approach to Evaluation of Thrombotic Microangiopathy

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT

Paolo Gresele Dipartimento di Medicina, Sezione di Medicina Interna e Cardiovascolare, Università di Perugia

Not So Benign Hematology Aplastic anemia, Paroxysmal Nocturnal Hemoglobinuria, atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura

Atypical Hemolytic-uremic Syndrome with impending CKD PRESENTED BY DR.NADEEM AZAD JR-3,DEPARTMENT OF PEDIATRICS

Introduction. Arif Asif 1 Ali Nayer 2 Christian S. Haas 3

Soliris and You. Your Guide To Living With ahus. INDICATION & IMPORTANT SAFETY INFORMATION FOR SOLIRIS (eculizumab)

Case Report Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature

Management of Rejection

Initial management of TMA syndromes

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

PREGNANCY ASSOCIATED THROMBOTIC THROMBOCYTOPENIC PURPURA AND ACUTE KIDNEY INJURY

Thrombotic microangiopathy (TMA) has been considered

monoclonal gammopathy of undetermin Citation Rheumatology international, 33(1),

M.Weitz has documented that he has no relevant financial relationships to disclose or conflict of interest to resolve.

Specialised Services Policy: CP98 Eculizumab for Atypical Haemolytic Uraemic Syndrome (ahus)

Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy

Soliris. Soliris (eculizumab) Description

Thrombotic thrombocytopenic purpura: a look at the future

Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis,

Recent advances in pathogenesis & treatment of ahus

Supplementary Appendix

THROMBOTIC MICROANGIOPATHY (TMA) BANFF WORKING GROUP. Marjan Afrouzian, Chair

Challenges in Renal Apheresis. Mark E. Williams MD, FACP, FASN Director, Renal Apheresis Beth Israel Deaconess Medical Center Harvard Medical School

CASE REPORT. Introduction. Case Report

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Supplementary Appendix

Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)

Atypical Subacute Recurrence of Catastrophic Antiphospholipid Syndrome in a Japanese Female Patient

Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation

Thrombotic Microangiopathy secondary to Malignant Hypertension presenting as acute Kidney injury-a Case Report

Case 1. Vascular disease and the kidney. Hypertension Affects Approximately 65 Million Americans: 28% of Adults. Renal disease causes hypertension

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO

Agenda. Management of Accelerated Hypertension (Updated in 2017) Salwa Roshdy Prof. of Cardiology Assiut University CardioEgypt 23/2/2017 2/27/2017

Urinalysis Negative for Blood or Protein

Sara K. Vesely, James N. George, Bernhard Lämmle, Jan-Dirk Studt, Lorenzo Alberio, Mayez A. El-Harake, and Gary E. Raskob

Biopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary

Medical Policy. MP Eculizumab (Soliris) Related Policies None. Last Review: 01/24/2019 Effective Date: 04/25/2019 Section: Prescription Drug

Lab 3, case 1. Is this an example of nephrotic or nephritic syndrome? Why? Which portion of the nephron would you expect to be abnormal?

When a patient presents with TMA, identify the underlying cause for the appropriate diagnosis... IS IT TTP OR IS IT ahus?

Renal Disease. Please refer to the assignment page Three online modules TBLs

ANCA-Negative Pulmonary-Renal Syndrome with Pathologic Findings Suggesting Thrombotic Thrombocytopenic Purpura

RaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable

PNH ahus gmg. Dosing and Administration Guide

Thrombotic Microangiopathy (TMA) The Clinical Facets of TMA

TMA CASE STUDY. Pamela Harmon, RN & Keturah Tomlin, RN Toronto General Hospital Apheresis Unit

HUS-MPGN-TTP. & related disorders

An Outbreak of E. coli O 157 Germantown, Ohio July 2012

Coding... 5 Benefit Application... 5 Description of Services... 6 Clinical Evidence... 7

PNH ahus. Dosing and Administration. For Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (ahus) patients

Transcription:

A 23 year old Caucasian male presented with shortness of breath, hypertension, bloody sputum, and a history of drug abuse (confirmed by urinalysis). He was found to have severe kidney injury requiring dialysis, hematuria, proteinuria, anemia and thrombocytopenia. A renal biopsy was performed.

Masson trichrome stain

Edematous intimal expansion

Schistocytes

H&E stain Myxoid / mucoid intimal expansion

Interlobular Artery Stained for Fibrin Trichrome Stain Anti fibrin

H&E stain Thick walls with GBM remodeling

Expanded Subendothelial Zone Obliterative Capillary Remodeling

Swollen Endothelial Cells (Endotheliosis)

TTP-TMA, HUS-TMA and preeclampsia result from injury to endothelial cells Normal glomerular capillary with patent lumen TTP-TMA with platelet-rich thrombus HUS-TMA with subendothelial expansion Preeclampsia with endotheliosis Anti-VEGF therapy with hybrid lesion

Thrombotic Microangiopathy (TMA) Thrombocytopenia, MAHA, fever, neurologic and renal abnormalities; low ADAMTS-13 (<10% actionable) Thrombotic Thrombocytopenic Purpura (TTP) Thrombocytopenia, MAHA and renal abnormalities; > 10% ADAMTS-13 Hemolytic Uremic Syndrome (HUS)

Thrombotic Microangiopathy (TMA) Thrombocytopenia, MAHA, fever, neurologic and renal abnormalities; low ADAMTS-13 (<10% actionable) Thrombotic Thrombocytopenic Purpura (TTP) Thrombocytopenia, MAHA and renal abnormalities; > 10% ADAMTS-13 Hemolytic Uremic Syndrome (HUS) No diarrhea (D- HUS) Diarrhea (D+ HUS) Shiga-toxin producing infection, e.g. E coli Atypical HUS Typical HUS Complement dysregulation Drug abuse Pregnancy associated Prescriptio n drugs Systemic sclerosis Radiation induced APL syndrome Malignant HTN Strep pneumonia HUS Many others

Pathologic Patterns of Thrombotic Microangiopathy TTP-TMA with plateletrich thrombus HUS-TMA with subendothelial expansion Preeclampsia with endotheliosis

Thrombotic Thrombocytopenic Purpura (TTP) Capillary Thrombi Glomeruloid Structure Endothelialized Thrombus

HUS LM Thick walls Fibrinoid Necrosis (H&E) Schistocytes (H&E)

HUS Arterial Lesions Fibrinoid necrosis Intimal expansion obliterating lumen Schistocytes

Thrombotic thrombocytopenic purpura (TTP)- like illness associated with intravenous Opana ER abuse-tennessee, 2012. Centers for Disease Control and Prevention. Morb Mortal Wkly Rep. 2013 Jan 11;62(1):1-4. In August 2012, a nephrologist reported to the Tennessee Department of Health (TDH) three cases of unexplained thrombotic thrombocytopenic purpura (TTP). By the end of October, a total of 15 such cases had been reported. A case-control study determined that the cases were associated with dissolving and injecting tablets of Opana ER (Endo Pharmaceuticals). Note: The cases were described as TTP-like, but the pathology clearly is HUS-type rather than TTP-type TMA.

Opana ER abuse and thrombotic thrombocytopenic purpura (TTP)-like illness: a rising risk factor in illicit drug users. Kapila A, et al. BMJ Case Rep. 2014 Mar 3;2014. From Tennessee Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extendedrelease formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Ambruzs JM, Serrell PB, Rahim N, Larsen CP. Am J Kidney Dis. 2014 Jun;63(6):1022-6. Two from Tennessee, one from Idaho Note: The cases were described as TTP-like, but the pathology clearly is HUS-type rather than TTP-type TMA.

Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extendedrelease formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Ambruzs JM, Serrell PB, Rahim N, Larsen CP. Am J Kidney Dis. 2014 Jun;63(6):1022-6.

Successful treatment of intravenously abused oral Opana ER-induced thrombotic microangiopathy without plasma exchange. Miller PJ, Farland AM, Knovich MA, Batt KM, Owen J. Am J Hematol. 2014 Jul;89(7):695-7. Resurgence of intravenous Opana as a cause of secondary thrombotic thrombocytopenic purpura. Rane M, Aggarwal A, Banas E, Sharma A. Am J Emerg Med. 2014 Aug;32(8):951.e3-4.

Diagnosis: Hemolytic Uremic Syndrome (HUS) type Thrombotic Microangiopathy (TMA), consistent with Opana-induced TMA